Tolerance and Toxicity of the PARP Inhibitor Olaparib in Older Women with Ovarian Cancer

被引：1
|
作者：
Dockery, L. [1 ]
Tew, W. [2 ]
Moore, K. [1 ]
Ding, K. [1 ]
机构：
[1] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
GYNECOLOGIC ONCOLOGY | 2017年 / 147卷 / 01期
关键词：
D O I：
10.1016/j.ygyno.2017.07.029
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：197 / 198
页数：2
相关论文
共 50 条
  • [1] Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer
    Dockery, Lauren E.
    Tew, William P.
    Ding, Kai
    Moore, Kathleen N.
    [J]. GYNECOLOGIC ONCOLOGY, 2017, 147 (03) : 509 - 513
  • [2] Olaparib: a promising PARP inhibitor in ovarian cancer therapy
    Ying Chen
    Lei Zhang
    Quan Hao
    [J]. Archives of Gynecology and Obstetrics, 2013, 288 : 367 - 374
  • [3] Olaparib: a promising PARP inhibitor in ovarian cancer therapy
    Chen, Ying
    Zhang, Lei
    Hao, Quan
    [J]. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2013, 288 (02) : 367 - 374
  • [4] Olaparib, PARP1 inhibitor in ovarian cancer
    Marchetti, Claudia
    Imperiale, Ludovica
    Gasparri, Maria Luisa
    Palaia, Innocenza
    Pignata, Sandro
    Boni, Terenzio
    Bellati, Filippo
    Panici, Pierluigi Benedetti
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (10) : 1575 - 1584
  • [5] Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer
    Gunderson, Camille C.
    Moore, Kathleen N.
    [J]. FUTURE ONCOLOGY, 2015, 11 (05) : 747 - 757
  • [6] PRECLINICAL STUDIES OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IMATINIB IN BRCA STRATIFIED OVARIAN CANCER
    Matheson, E.
    Salehan, M.
    Mukhopadhyay, A.
    Curtin, N. J.
    Drew, Y.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 673 - 673
  • [7] PARP-Inhibitor Olaparib in the Treatment of Ovarian Clear Cell Cancer: Predictors of Sensitivity and Resistance
    Dedes, K. J.
    Wilkerson, P.
    Wetterskog, D.
    Lambros, M. B.
    Natrajan, R.
    Tan, D. S.
    Campion-Flora, A.
    Rodrigues, D. N.
    Gauthier, A.
    Daley, F.
    Lord, C. J.
    Kaye, S. B.
    Ashworth, A.
    Reis-Filho, J. S.
    [J]. LABORATORY INVESTIGATION, 2012, 92 : 265A - 265A
  • [8] Adherence to PARP inhibitor therapy among women with ovarian cancer
    Moss, Haley A.
    Chen, Ling
    Hershman, Dawn L.
    Davidson, Brittany
    Wright, Jason D.
    [J]. GYNECOLOGIC ONCOLOGY, 2021, 163 (02) : 262 - 268
  • [9] PARP-Inhibitor Olaparib in the Treatment of Ovarian Clear Cell Cancer: Predictors of Sensitivity and Resistance
    Dedes, K. J.
    Wilkerson, P.
    Wetterskog, D.
    Lambros, M. B.
    Natrajan, R.
    Tan, D. S.
    Campion-Flora, A.
    Rodrigues, D. N.
    Gauthier, A.
    Daley, F.
    Lord, C. J.
    Kaye, S. B.
    Ashworth, A.
    Reis-Filho, J. S.
    [J]. MODERN PATHOLOGY, 2012, 25 : 265A - 265A
  • [10] TOLERABILITY AND TOXICITY OF PARP INHIBITORS IN WOMEN WITH EPITHELIAL OVARIAN CANCER - A REAL WORLD COMPARISON BETWEEN OLDER AND YOUNGER WOMEN
    Low, Samantha
    Crearie, Christine
    Brown, Jennifer
    Randhawa, Manreet
    Glasspool, Rosalind
    Roxburgh, Patricia
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A158 - A158
12345